Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43920276" target="_blank" >RIV/00216208:11120/20:43920276 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/20:10412554 RIV/00064211:_____/20:W0000016

Result on the web

<a href="https://doi.org/10.1111/jdv.16771" target="_blank" >https://doi.org/10.1111/jdv.16771</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jdv.16771" target="_blank" >10.1111/jdv.16771</a>

Result language

angličtina

Original language name

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic

Original language description

Patient concerns about the possible increased susceptibility to coronavirus disease 19 (COVID-19) infection or a more severe course of the disease when treated with immunosuppressive therapy may lead to lower treatment compliance. Treatment safety concerns were significantly more commonin the biologics-treated patients, where 40.7% either agreed/strongly agreed of having experienced an increased risk of COVID-19 infection as compared to 21.3% in the conventional systemic group (P&lt;0.01) and 10.9% in the topical therapy group (P&lt;0.00001). This study has limitations. Patient anxiety is affected by the severity of psoriasis, but in our study, patients on biologics hadrecently a milder case of the disease than patients in the other groups. It is also possible that the relationship between psoriasis treatment and anxiety could be indirect (e.g. due to unmeasured confounding) and not a direct consequence of the COVID-19 pandemic.In conclusion, the overall compliance of biologic treatment of patients with psoriasis during the COVID-19 pandemic lock-down was extremely good despite expressing anxiety and more frequent concerns about the safety of their treatment compared to patients on other therapies.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of the European Academy of Dermatology and Venereology

ISSN

0926-9959

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

11

Country of publishing house

GB - UNITED KINGDOM

Number of pages

3

Pages from-to

"e682"-"e684"

UT code for WoS article

000546564300001

EID of the result in the Scopus database

2-s2.0-85087730121